Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data

被引：0

作者：

Heran Deng

Liying Wang

Na Wang

Kejin Zhang

Yanxia Zhao

Pengfei Qiu

Xiaowei Qi

Danhua Zhang

Fei Xu

Jieqiong Liu

机构：

[1] Sun Yat-Sen Memorial Hospital,Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center

[2] Sun Yat-Sen University,State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine

[3] Sun Yat-Sen University Cancer Center,undefined

[4] Sun Yat-Sen University,undefined

[5] Xiangya Hospital of Central South University,undefined

[6] Center South University,undefined

[7] Union Hospital Tongji Medical College Huazhong University of Science and Technology,undefined

[8] Huazhong University of Science and Technology,undefined

[9] Shandong Tumor Hospital,undefined

[10] Shandong university,undefined

[11] The Southwest Hospital of AMU,undefined

[12] Army Medical University,undefined

[13] The Second Xiangya Hospital of Central South University,undefined

[14] Center South University,undefined

来源：

BMC Cancer | / 23卷

关键词：

Tripe-negative breast cancer; Neoadjuvant immunotherapy; Anti-PD-1/L1 antibody; Real-world study;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 363 条

[11]

Mao X(2020)Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women with Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial JAMA Onco. l6 676-821

[12]

Loi S(2020)Pembrolizumab for Early Triple-Negative Breast Cancer N Engl J Med 382 810-1288

[13]

Michiels S(2019)A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study Ann Oncol 30 1279-543

[14]

Adams S(2022)Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study Ann Oncol 33 534-1100

[15]

Loibl S(2020)Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial Lancet 396 1090-520

[16]

Budczies J(2018)Breast Cancer Immunotherapy: Facts and Hopes Clin Cancer Res 24 511-173

[17]

Denkert C(2018)Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis BMJ 360 k793-82

[18]

Salgado R(2021)The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker Cancer Cell 39 154-2159

[19]

Chen DS(2020)Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World Multicenter Analysis Front Oncol 10 811-581

[20]

Mellman I(2021)Managing side effects of immune checkpoint inhibitors in breast cancer Crit Rev Oncol Hematol 162 103354-5434

← 1 2 3 4 5 6 7 8 9 10 →